切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2019, Vol. 12 ›› Issue (01) : 59 -62. doi: 10.3877/cma.j.issn.1674-6902.2019.01.011

所属专题： 文献；

论著

胸腺肽α1缓解EGFR-TKI对EGFR敏感突变NSCLC患者T淋巴细胞亚群抑制的研究
朱广阔1, 郑林鹏1, 杨峤1, 王洲飞1, 许子寒1, 孙建国1,†(), 陈正堂1,†()   
  1. 1. 400037　重庆，陆军军医大学（第三军医大学）新桥医院全军肿瘤研究所
  • 收稿日期:2018-11-07 出版日期:2019-02-20
  • 通信作者: 孙建国, 陈正堂
  • 基金资助:
    国家自然科学基金资助项目(81672841); 陆军军医大学院级课题(2014YLC08)

Thymosin α1 was able to relieve the inhibitory effect of EGFR-TKI on peripheral blood T lymphocyte subsets of the patients with non-small cell lung cancer

Guangkuo Zhu1, Linpeng Zheng1, Qiao Yang1, Zhoufei Wang1, Zihan Xu1, Jianguo Sun1,†(), Zhengtang Chen1,†()   

  1. 1. Cancer Institute of PLA, Xinqiao Hospital of Army Medical University, Chongqing 400037, China
  • Received:2018-11-07 Published:2019-02-20
  • Corresponding author: Jianguo Sun, Zhengtang Chen
  • About author:
    Corresponding author: Chen Zhengtang, Email: ;
    Sun Jianguo, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

朱广阔, 郑林鹏, 杨峤, 王洲飞, 许子寒, 孙建国, 陈正堂. 胸腺肽α1缓解EGFR-TKI对EGFR敏感突变NSCLC患者T淋巴细胞亚群抑制的研究[J]. 中华肺部疾病杂志(电子版), 2019, 12(01): 59-62.

Guangkuo Zhu, Linpeng Zheng, Qiao Yang, Zhoufei Wang, Zihan Xu, Jianguo Sun, Zhengtang Chen. Thymosin α1 was able to relieve the inhibitory effect of EGFR-TKI on peripheral blood T lymphocyte subsets of the patients with non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2019, 12(01): 59-62.

目的

探讨表皮生长因子受体(EGFR)敏感突变非小细胞肺癌(NSCLC)患者接受EGFR-TKI单药，以及EGFR-TKI联合胸腺肽α1治疗前后外周血T淋巴细胞亚群的变化。

方法

采集我院2008年5月至2018年8月期间接受单药EGFR-TKI和EGFR-TKI联合胸腺肽α1治疗的NSCLC患者的外周血T淋巴细胞亚群数据。

结果

在患者EGFR-TKI耐药前，患者接受EGFR-TKI单药治疗后外周血CD4＋ T淋巴细胞，CD8＋ T淋巴细胞，CD3＋ T淋巴细胞数量较接受EGFR-TKI单药治疗之前显著降低(P<0.05)；患者接受EGFR-TKI联合胸腺肽α1治疗后外周血CD4＋ T淋巴细胞，CD8＋ T淋巴细胞，CD3＋ T淋巴细胞数量与EGFR-TKI单药治疗前相比稍降低，但无统计学差异(P>0.05)。

结论

胸腺肽α1在某种程度上可以缓解EGFR-TKI对EGFR突变NSCLC患者外周血T淋巴细胞亚群的抑制。

关键词: 抑制剂，表皮生长因子受体，酪氨酸激酶, 胸腺肽α1, T淋巴细胞亚群
Objective

Comparative analysis of peripheral blood T lymphocyte subsets before patients treated with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) and patients after receiving EGFR-TKI monotherapy or combined with Thymosin α1 therapy.

Methods

The data of peripheral blood T lymphocyte subsets of patients receiving EGFR-TKI and EGFR-TKI combined with Thymosin α1 was collected from May 2008 to August 2018.

Results

The number of Peripheral blood CD4+ , CD8+ and CD3+ T lymphocyte of patients were decreased after EGFR-TKI treatment alone(P<0.05), the number of those T lymphocytes shown no difference before EGFR-TKI monotherapy and after receiving EGFR-TKI plus Thymosin α1 therapy (P>0.05).

Conclusions

EGFR-TKI could decrease the peripheral blood T lymphocyte subsets of patients treated with EGFR-TKI, thymosin α1 was able to reverse the inhibitory effect of EGFR-TKI on peripheral blood T lymphocyte subsets of patients to some extent.

Key words: Epidermal growth factor receptor tyrosine kinase inhibitor, Thymosin α1, T lymphocyte subsets
图1 27例EGFR敏感突变NSNCL患者接受EGFR-TKI治疗前后外周血T淋巴细胞亚群变化
图2 8例EGFR敏感突变NSNCL患者接受EGFR-TKI治疗前与EGFR-TKI治疗联合胸腺肽α1后外周血T淋巴细胞亚群变化
图3 3例EGFR敏感突变NSNCL患者接受EGFR-TKI治疗前、EGFR-TKI治疗后、EGFR-TKI治疗联合胸腺肽α1后三阶段外周血T淋巴细胞亚群变化
1
钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-6.
2
Bray F,Ferlay J,Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
3
Herbst RS,Heymach JV,Lippman SM. Lung cancer [J]. N Engl J Med, 2008, 359(13): 1367-1380.
4
Allemani C,Weir HK,Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25，676，887 patients from 279 population-based registries in 67 countries (CONCORD-2)[J]. Lancet, 2015, 385(9972): 977-1010.
5
Rosell R,Carcereny E,Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3): 239-246.
6
Watanabe S,Inoue A,Nukiwa T, et al. Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion[J]. Anticancer Res, 2015, 35(12): 6957-6961.
7
Zhou C,Wu YL,Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8): 735-742.
8
Han JY,Park K,Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung[J]. J Clin Oncol, 2012, 30(10): 1122-1128.
9
de Visser KE,Eichten A,Coussens LM. Paradoxical roles of the immune system during cancer development[J]. Nat Rev Cancer, 2006, 6(1): 24-37.
10
Luo Q,Gu Y,Zheng W, et al. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway[J]. Toxicol Appl Pharmacol, 2011, 251(2): 130-136.
11
Danielli R,Cisternino F,Giannarelli D, et al. Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy[J]. Expert Opin Biol Ther, 2018, 18(sup1): 77-83.
12
Garaci E,Pica F,Matteucci C, et al. Historical review on thymosin alpha1 in oncology: preclinical and clinical experiences[J]. Expert Opin Biol Ther, 2015, 15 Suppl 1: S31-S39.
13
Jiang J,Wang X,Tian J, et al. Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials[J]. Thorac Cancer, 2011, 2(4): 213-220.
14
余荣，孙宇，蔡庆，等. α1胸腺肽减轻放射性肺损伤[J]. 中国肺癌杂志，2011, 14(3): 187-193.
15
Moody TW,Fagarasan M,Zia F, et al. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo[J]. Cancer Res, 1993, 53(21): 5214-5218.
16
Garaci E,Pica F,Serafino A, et al. Thymosin alpha1 and cancer: action on immune effector and tumor target cells[J]. Ann N Y Acad Sci, 2012, 1269: 26-33.
17
Wee P,Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways[J]. Cancers (Basel), 2017, 9(5)．
18
Li M,Ong SS,Rajwa B, et al. The SH3 domain of Lck modulates T-cell receptor-dependent activation of extracellular signal-regulated kinase through activation of Raf-1[J]. Mol Cell Biol, 2008, 28(2): 630-641.
19
Roskoski RJ. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors[J]. Pharmacol Res, 2014, 87: 42-59.
20
Knutsen AP,Freeman JJ,Mueller KR, et al. Thymosin-alpha1 stimulates maturation of CD34＋ stem cells into CD3＋4＋ cells in an in vitro thymic epithelia organ coculture model[J]. Int J Immunopharmacol, 1999, 21(1): 15-26.
21
Romani L,Bistoni F,Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling[J]. Blood, 2004, 103(11): 4232-4239.
22
Jennings RN,Grayson JM,Barton ES. Type I interferon signaling enhances CD8＋ T cell effector function and differentiation during murine gammaherpesvirus 68 infection[J]. J Virol, 2014, 88(24): 14040-14049.
[1] 马燕, 郭莉娜, 李灿, 严伟恒, 刘月明, 邓峰美, 刘卫华, 刘漪沦. 重度烧伤患者血糖与炎性因子及免疫功能的相关性研究[J]. 中华损伤与修复杂志(电子版), 2018, 13(04): 273-277.
[2] 陈惠丽, 刘曦, 黄珊凤, 邵迪, 夏瑾瑜. 新型冠状病毒肺炎患者外周血T淋巴细胞亚群变化[J]. 中华实验和临床感染病杂志(电子版), 2021, 15(02): 99-104.
[3] 张薇, 孙浩淼, 王洁. 手足口病患儿外周血CXC趋化因子配体10表达、T细胞及细胞因子与预后的相关性[J]. 中华实验和临床感染病杂志(电子版), 2019, 13(03): 239-244.
[4] 夏爽, 曹敏, 席翔. 后腹腔镜肾部分切除术治疗老年T1b期肾癌对患者血清T淋巴细胞亚群及预后生存的影响[J]. 中华腔镜泌尿外科杂志(电子版), 2021, 15(05): 406-410.
[5] 陈双, 李莲, 彭余, 杨再林. T淋巴细胞及细胞因子在预测肺炎重症转化中的临床意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(05): 750-753.
[6] 泽仁尼玛, 杨建蓉, 李明琴, 陈颖. 阿莫西林/克拉维酸钾对肺结核患者淋巴细胞亚群CD4水平的意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(01): 61-63.
[7] 严锡祥, 郑爱东, 张振恩, 潘国翠, 崔永华. 胸腺肽α1免疫治疗联合抗感染对重症肺部感染的影响[J]. 中华肺部疾病杂志(电子版), 2021, 14(03): 301-304.
[8] 吴桂辉, 黄涛, 罗槑, 蔡阳, 任利红. 活动性肺结核患者病情严重程度与维生素D及T细胞亚群的相关性分析[J]. 中华肺部疾病杂志(电子版), 2020, 13(04): 510-512.
[9] 陈艳丽, 王媛媛, 张勇, 李文洁. 中晚期非小细胞肺癌患者化疗前后T淋巴细胞亚群表达差异分析及临床意义[J]. 中华肺部疾病杂志(电子版), 2020, 13(01): 13-17.
[10] 唐艳林, 王锋, 刘自刚, 何源. 外周血T淋巴细胞亚群及早期炎症标志物表达对老年非小细胞肺癌化疗预后的影响分析[J]. 中华细胞与干细胞杂志(电子版), 2020, 10(02): 97-102.
[11] 韩永清, 饶敏超, 傅峰, 黄开荣. 参芪十一味颗粒联合FOLFOX4方案化疗对晚期结直肠癌患者的近期疗效及其对血清IL-35、IL-37和T淋巴细胞亚群的影响[J]. 中华临床医师杂志(电子版), 2022, 16(05): 400-404.
[12] 马静静, 伍丹丹, 张吉翔, 朱刚艳, 陈国忠, 杨英杰, 雷媛, 苏文豪, 董卫国. 新冠肺炎患者外周血T淋巴细胞亚群的变化及意义[J]. 中华临床医师杂志(电子版), 2020, 14(10): 759-763.
[13] 张建梅, 刘发盛, 陈欣, 朱振华. 新生儿高胆红素血症诊治中T淋巴细胞和白介素-6变化的研究[J]. 中华临床医师杂志(电子版), 2018, 12(10): 571-575.
[14] 黄山, 吕松琴, 张娟, 徐丽萍, 李佳能, 李晓非. 云南地区新发艾滋病合并其他病原微生物感染患者外周血T淋巴细胞亚群分布特征初探[J]. 中华临床实验室管理电子杂志, 2023, 11(01): 16-20.
[15] 罗俐梅, 罗娅, 蔡宜含, 冯伟华, 蔡蓓. 外周血淋巴细胞绝对计数在结直肠癌和食管癌肿瘤进展与治疗前后免疫状态评估的临床应用研究[J]. 中华临床实验室管理电子杂志, 2019, 07(03): 137-144.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号